Phase I trial will evaluate seasonal and avian flu vaccine.

Encorium Group received a Phase I trial contract for approximately $1.2 million. This contract is in support of an innovative approach to the development of a vaccine for the prevention of multiple types of influenza, including seasonal and pandemic avian flu.

Encorium will provide consulting on clinical trial design and protocol development, project and study site management and monitoring, data management, and biostatistical support. Revenue recognition will begin in the first quarter of 2007 on a proportional performance basis over the life of the contract as services are performed.

Previous articleSalix Purchases Pepcid and Diuril from Merck & Co. for $55M
Next articleApplied Biosystems and MDS SCIEX Launched Software Development Initiative